CJRB-201 / CJ Biosci - LARVOL DELTA

CJ Bioscience to Present Preclinical Data on Inflammatory Bowel Disease Pipeline Candidate CJRB-201 at ’ECCO 2025’; Clinical Entry Targeted for 2026 (PRNewswire) - "Among 60 Faecalibacterium strains analyzed, CJRB-201 exhibited the strongest ability to induce regulatory T cells (Tregs), which play a critical role in mitigating immune dysregulation. In mouse models, CJRB-201 significantly improved key disease markers, including inhibition of weight loss, reduction in disease activity index, histopathological improvement, suppression of pro-inflammatory cytokine secretion, and improvement of colon length. Notably, CJRB-201 demonstrated comparable efficacy to an antibody-based therapy in a preclinical model while offering additional advantages in safety and oral convenience...The company also announced its plan to initiate its first-in-human study in 2026 based on the promising preclinical results."

New trial • Preclinical • Inflammatory Bowel Disease

CJ Bioscience to Present Preclinical Data on Microbiome New Drug at 'ECCO 2025' [Google translation] (HIT News) - "The company explained that it is developing CJRB-201 as a follow-up pipeline to its main pipeline, ‘CJRB-101,’ and that it plans to disclose its anti-inflammatory effects and mechanism of action through immune analysis and animal testing at this conference...According to the company, the research team discovered that among 60 strains of the Faecalibacterium genus, CJRB-201 most effectively induced regulatory T cells (Treg) with immune-regulating functions. In addition, in a mouse experimental model, it confirmed the effects of improving major disease indicators, such as suppressing weight loss, improving disease activity index, alleviating tissue pathology, suppressing inflammatory cytokine secretion, and improving colon length....'Based on the results of this study, we plan to begin full-scale clinical development in 2026.'"

Preclinical • Inflammatory Bowel Disease

CJRB-201, a promising candidate for microbiome-based therapy with potent anti-inflammatory effects in Inflammatory Bowel Disease (ECCO-IBD 2025) - "Conclusion CJRB-201 exhibits superior anti-inflammatory efficacy in multiple immune assays and IBD animal models, significantly improving preclinical and inflammatory markers. Given its ability to enhance T reg populations and the promising potential of the identified fiber in supporting its colonization, CJRB-201 holds strong promise as a microbiome-based therapeutic for IBD patients."

Crohn's disease • Immunology • Inflammation • Inflammatory Bowel Disease • IFNG • IL10 • IL1B • LCN2